Results 31 to 40 of about 12,723,792 (140)

Nonpathogenic SIV Infection in Sooty Mangabeys Is Characterized by a Lack of Activation and Expansion of Monocytes

Journal of Medical Primatology, Volume 55, Issue 5, October 2026.
ABSTRACT Introduction Natural hosts of simian immunodeficiency virus (SIV), including sooty mangabeys (SMs), maintain high viremia without progressing to AIDS and AIDS‐associated histopathogenesis. The mechanisms underlying this protection and lack of pathogenesis remain incompletely understood, particularly in relation to monocyte/macrophage ...
Caroline Soulas, Hai Duc Nguyen, Summer Siddiqui, Natalie Stahr, Tricia H. Burdo, Francis J. Novembre, Woong‐Ki Kim, Kenneth C. Williams   +7 more
wiley   +1 more source

Complement-Mediated Virus Infectivity Neutralisation by HLA Antibodies Is Associated with Sterilising Immunity to SIV Challenge in the Macaque Model for HIV/AIDS. [PDF]

, 2014
Sterilising immunity is a desired outcome for vaccination against human immunodeficiency virus (HIV) and has been observed in the macaque model using inactivated simian immunodeficiency virus (SIV).
Mark Robinson, Hassall, M, Stott James, Quartey-Papafio, R, Martin Cranage, Cranage, M, Page Mark, James Stott, Robinson Mark, Mark Hassall, Mark Page, Robinson, M, Quartey-Papafio Ruby, Page, M, Neil Almond, Hassall Mark, Almond, N, Almond Neil, Ruby Quartey-Papafio, Cranage Martin, Stott, J   +20 more
core   +1 more source

Real‐World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug‐Resistant HIV‐1 in Southeastern France

Journal of Medical Virology, Volume 98, Issue 9, September 2026.
ABSTRACT Lenacapavir and fostemsavir, two recently approved anti‐HIV‐1 agents, are promising options for people with difficult‐to‐treat HIV; however, real‐world data remain limited. This study aimed to describe the epidemiological, clinical, and virological profiles of people receiving combination antiretroviral regimens, including lenacapavir and/or ...
Syrine Boujamline, Celine Boschi, Hugo Bes‐Barlandier, Christelle Tomei, Amelie Menard, Saadia Mokhtari, Isabelle Ravaux, Yacine Belkhir, Nadege Neant, Caroline Solas, Philippe Colson, Matthieu Million   +11 more
wiley   +1 more source

Disease progression in Human Immunodeficiency Virus type 1 infected viraemic controllers [PDF]

, 2012
PhDBackground: The mechanism of CD4+ T-cell decline in Human Immunodeficiency Virus-1 (HIV-1) infection is unclear, but the association with plasma HIV-1 RNA-load suggests viral replication is involved.
Groves, Katherine Claire
core   +4 more sources

Targeting Human Immunodeficiency Virus Integrase Beyond the Active Site: The Discovery and Development of Allosteric Integrase Inhibitors

ChemMedChem, Volume 21, Issue 16, 27 August 2026.
Human immunodeficiency virus (HIV) allosteric integrase inhibitors (ALLINIs) offer a vital alternative to standard therapies by targeting noncatalytic sites. By inducing aberrant integrase multimerization, they disrupt viral maturation. This review explores their medicinal chemistry evolution, detailing structural insights, structure–activity ...
Francesco Saccoliti, Elisa Patacchini, Emanuele Cara, Laura Zarbo, Antonella Messore, Aurora Albano, Giuseppe Ruggieri, Valentina Noemi Madia, Luigi Scipione, Roberta Costi, Roberto Di Santo   +10 more
wiley   +1 more source

Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus [PDF]

, 2006
The feline homologue of CD134 (fCD134) is the primary binding receptor for feline immunodeficiency virus (FIV), targeting the virus preferentially to activated CD4+ helper T cells.
McMonagle, E.L., Hosie, M.J., Willett, B.J., Ridha, S.   +3 more
core   +1 more source

Development of retroviral vectors for selective gene transfer into haematopoietic precursor cells and investigation of the gamma-retroviral R-peptide mediated membrane fusion [PDF]

, 2009
Eine in vivo Modifizierung von Blutstammzellen wäre für eine Reihe gentherapeutischer Therapieansätze vorteilhaft. Dies würde voraussetzen, dass retrovirale Vektoren gezielt auf Blutstammzellen ausgerichtet werden können.
Bobkova, Maria
core  

Murine leukemia virus (MLV) replication monitored with fluorescent proteins [PDF]

, 2006
Background: Cancer gene therapy will benefit from vectors that are able to replicate in tumor tissue and cause a bystander effect. Replication-competent murine leukemia virus (MLV) has been described to have potential as cancer therapeutics, however, MLV
Erlwein, Otto, Bittner, Alexandra, Sliva, Katja, Schnierle, Barbara   +3 more
core   +1 more source

Construction and characterization of chimaeric human immunodefiency virus type 1 subtype C Gag virus-like particles [PDF]

, 2006
Includes bibliographical references (leaves 114-128).In this study I explored the possibility of making HIV-1 subtype C Pr55gag-based chimaeric virus-like particles (VLPs) as a boost to the HIV-IC multigene DNA vaccine pTHr.grttnC, which encodes a ...
Halsey, Richard James
core   +1 more source

Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives

MedComm, Volume 7, Issue 7, July 2026.
Schematic illustration of four emerging CRISPR–Cas delivery platforms defined by distinct design principles and structural features: virus‐mimicking nanosystems (e.g., VLPs), cell‐derived extracellular vesicles, cell‐penetrating peptides, and stimuli‐responsive scaffolds. These platforms enable spatiotemporally controlled delivery of RNPs, mRNA, or DNA
Meijia Yang, Yiqiong Song, Ziyang Wang, Ke Chao, Lifeng Li, Xu Zhang, Xiaoran Duan, Chenglong Yu, Ruyue Xue, Jie Zhao   +9 more
wiley   +1 more source